Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

asciminib

- PMLiVE

Amgen and Kite in $1bn cancer immunotherapy tie up

Latest major research deal in growing area of oncology

Novartis day

FDA close to first biosimilar approval

US regulator’s advisory board recommends Novartis’ version of Amgen’s Neupogen

- PMLiVE

Angelini to market Ariad’s Iclusig in Eastern Europe

Comes after leukaemia drug passes EMA safety review

- PMLiVE

Japan first to approve Novartis psoriasis drug Cosentyx

Becomes first company to gain approval for an interleukin-17 inhibitor

- PMLiVE

Novartis’ acromegaly therapy cleared by FDA

Signifor LAR shows superior efficiency to older treatments

- PMLiVE

NICE backs Pfizer drug in kidney cancer

Inlyta near end of two-year struggle for recommendation

- PMLiVE

Novartis’ Afinitor fails frontline breast cancer trial

Drug already approved to treat HER2-negative breast cancer

- PMLiVE

Novartis’ Cosentyx beats Stelara in psoriasis study

Cosentyx achieved clearance in 70% of patients

- PMLiVE

Cancer care celebrated at awards

QiC Oncology programme recognises teams working to improve patient outcomes in oncology

Sanofi reception

Sanofi and Evotec discuss high-level outsourcing alliance

Partnership to focus on cancer drug discovery

- PMLiVE

NICE backtracks on Gazyvaro rejection

Roche agrees to patient access scheme to help gain leukaemia recommendation

- PMLiVE

Succinct and ecancer team up on oncology education events

Will work together to support HCPs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links